Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I bought at 65 cents and am still in it.
Nice little jump this morning on this totally undervalued gem...
CYDY has the COM patent for highly concentrated LL. Expires in 2031 SK said on the last call. Read/listen to the transcript. He says it loud and clear.
Mrmd announced earnings after the bell today. Anyone interested?
That’s how money is doled out in a grant. The announcement comes first. Then you do the work and some money is sent in periodic milestones and at the conclusion of the work, the final amount is sent.
There is no such thing as received because either the full payment is held until the end of the work or a couple of incremental payments are sent.
This is such an important piece of today's PR. Is Lalezari speculating? CytoDyn would not be releasing a PR without being damn certain that Leronlimab can effectuate this incredible result. And coupled with the new president, the share price can only go up from here.
“The potential for a one-time gene therapy encoding a protein such as leronlimab represents a great hope for the future of HIV therapy and functional cure. Currently, cells deficient in CCR5 have demonstrated a potential path to HIV cure, and bone marrow transplant is not an option for most patients because it is risky and highly invasive. We look forward to exploring this critical area with the assistance of the NIH and advancing research with hopes of finding a functional cure and helping to end the HIV pandemic.”
More facts that Leronlimab is real:
A published fact in this passage: high recovery rate
Conclusions: Leronlimab appeared safe and well tolerated. The high recovery rate suggested benefit, and those with lower inflammatory markers had better outcomes. Some, but not all, patients appeared to have dramatic clinical responses, indicating that unknown factors may determine responsiveness to leronlimab. Routine inflammatory and cell prognostic markers did not markedly change immediately after treatment, although interleukin-6 tended to fall. In some persons, C-reactive protein clearly dropped only after the second leronlimab dose, suggesting that a higher loading dose might be more effective.
Shorter's paradise.
Traders pulling their money out before the weekend.
Speculators taking profits.
Don't panic.
All of these statements are soooo irrelevant. We know that CYDY has virtually no money. So, what's your point?
Moreover, the new President starts tomorrow. So, what's your point?
Who cares what he bought and sold in his personal life. If he turns CYDY around,
which I'm praying (because you may not have anything to really say), then the
shareholders will be happy with the upswing in the share price.
Beautiful! Beautiful self-encapsulated regimen.
Here's more verbatim - you'll like this - and a good buzz phrase: STRONG PRECLINICAL EVIDENCE
This is about leronlimab, one's favorite saline fluid
Results: Herein, leronlimab was shown to bind CCR5 in multiple breast cancer cell lines. Binding of leronlimab to CCR5 reduced ligand-induced Ca+ 2 signaling, invasion of TNBC into Matrigel, and transwell migration. Leronlimab enhanced the BCa cell killing of the BCa chemotherapy reagent, doxorubicin. In xenografts conducted with Nu/Nu mice, leronlimab reduced lung metastasis of the TNBC cell line, MB-MDA-231, by > 98% at 6 weeks. Treatment with leronlimab reduced the metastatic tumor burden of established TNBC lung metastasis.
Conclusions: The safety profile of leronlimab, together with strong preclinical evidence to both prevent and reduce established breast cancer metastasis herein, suggests studies of clinical efficacy may be warranted.
chump change
And I was having such fun quoting verbatim!
An abundance of frivolous lawsuits will bankrupt this company.
Also, the writer/reviewer wrote preclinical model. You interpreted as trial. Wrong!
You pay your money - I said the article is behind a major paywall.
I performed my DD as a shareholder.
Now, it’s your turn to spend some money and get a copy of that article. AND prove me wrong.
I’m not sure you will be able because I transcribed that passage verbatim…
“LOL.” Does this mean you conduct research in a lab or are an oncology doc?
Yada, yada, yada.
Still laughing.
Laughing too - because access to the article is mandatory in order to read about Leronlimab - behind a major paywall!
It says enough about Leronlimab's efficacy that one might experience serious indigestion when the steadfast belief has been that leronlimab is (supposedly) saline.
Here is one of several instances where Leronlimab is mentioned in the article from Taylor and Francis online, a database of scientific journals. This particular journal, is aptly titled "Expert Opinion on Investigational Drugs." The Journal's overview is daunting and comprehensive: "Expert Opinion on Investigational Drugs [ISSN 1354-3784]; [e-ISSN 1744-7658] is a MEDLINE-indexed, international journal publishing rigorously peer-reviewed review articles and original papers on drugs in preclinical and early-stage clinical development, providing expert opinion on the scope for future development. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development."
INNATE IMMUNITY AS A TARGET FOR NOVEL THERAPEUTICS IN TRIPLE NEGATIVE BREAST CANCER
Page 117: The CCR5 antagonist leronlimab has demonstrated significant reduction of metastatic burden in preclinical models of metastatic breast cancer.
One last fact. This article went through a rigorous process for publication. "All manuscripts submitted to the journal are peer-reviewed in a double-blind fashion."
Again, just your opinion on a supposedly bogus chemical.
I wasn't referring to Covid-19.
Oh suuure, you are right. I'll listen to you and sell all my shares.
All good points. Thank you for bringing them to the fore.
Let's start with the "FDA DEBUNKS that one."
The FDA report was from May 2021. This is July 2022. I consider that old news and since that time, two studies have been published showing Leronlimab's effectiveness. The FDA hold will be lifted. As I said, you are winning on this one, but not for long.
You should really listen to the CC because it was stated that Samsung and CYDY are working out a payment plan.
You can say what you want about the 18 million now being reduced to 2 million. Just show me a tabulation sheet from CYDY, not your estimate.
Yup Friday's close was .397. I feel it more than you do but am not concerned about the stock price at all. The stock price has nothing to do with the effectiveness of Leronlimab. You and I know that the stock price is heavily manipulated - currently about forty million shares short. Some individuals are betting heavily against CYDY ascending ever again.
If all of those 40 million were not short, what would CYDY's stock price be right now?
Read those other studies to help you understand that Leronlimab is not saline.
As you know from past experience, you and I disagree on everything. With the previous CEO gone, my bet is on CYDY going up.
Those are some really good points.
Let's review what you just wrote:
"OMMFG- What the hell does that have to do with no BLA, no CEO, FDA clinical holds, London poster flop, and no money?" And, "Thats why this trash is trading in da 30s where it belongs...it really belongs at .01 but we'll get to that later when its confirmed by the official share price imo."
So, CYDY will have a boss come 9/8/22. CYDY coffers also raised an additional $18 million.
The FDA clinical hold has a timeline/timestop that CYDY has to fulfill before a hold is lifted. And it will be lifted. For the time being, your statement is winning.
London poster flop: If it was a flop, then it would not raise to the level of a poster.
Do we need a BLA, right now? No.
This CYDY trash closed at .41 cents, up from 25 cents a couple of months ago. I think we have seen the bottom. Now, we have to start clawing our way UP.
I think this is the most important/urgent argument for CYDY and I'm glad you brought it up in this discussion: the stock price "really belongs at .01..."
Then why hasn't it? In this past fifteen months, the stock price has plummeted to 25 cents but not lower. Why not?
In case I forget, the CC mentioned that CYDY is in talks with Samsung on a payment plan. That discussion precludes the stock price dropping below 25 cents.
I guess you heard in the CC about the "other" developments that will bolster the share price.
But to answer your question succinctly: why hasn't this trash dropped to a penny? CYDY has a drug called Leronlimab and that poster flop and in other studies, Leronlimab has shown an effectiveness that stays or saves a person from dying.
I believe that a person's life is worth more than a cent.
The share price is on the mend now that the prior CEO has been removed. Just a matter of a few months... we've held on this long. We have $19 million to make it a little longer.
Lastly, did you hear that piece of "trash" in the CC, where, you take a shot of Leronlimab and your body can produce more Leronlimab!? Is that worth more than a penny?
I was referring to the “suppressed image.”
I’m not worried.
As if - as if that shout out has any validity like yours
Huh?
The Titanic used diesel to propel it forward. CYDY uses Leronlimab and from what I can see, CYDY is still moving forward.
This morning, NPR, did a special on the new Hydrogen economy talking about the different colored hydrogens. Blue hydrogen does not need carbon capture and 4 hydrogen hubs in the Ohio Valley. Manchin is gunning one hub to be located in West Virginia. 8 billion program authorized to build out hubs. All kinds of products like fertilizer etc can me made from hydrogen…. Very interesting..
Tick tock
Went to five cents, actually!
If you know anything about the Medical State Board test, everyone who is taking it, assembles in one room, sits at a desk where the TEST is placed. You open it and for the next // hours you write out the answers. Then you leave. The completed test stays on the desk.
There is no such thing as you "don't hand in the paper." And thus, a grade is assigned to you.
Here I am. You gotta spend money to make money
I am not advocating a reverse split. I believe reverse splits in most cases are terrible but a friend of mine explained it to me quite simply: "It's a choice, when it's necessary because it is one tool in a company's tool shed that prevents bankruptcy."
There's a lot of talk about CYDY going under and soon. Well, in this one idea, a reverse split would do wonders. Check it out:
For the sake of talking, let's do a 10 for 1 reverse. Right now our stock would be $3.40 but the shorts would certainly bring it down to $2.
But here's the real kick that no one addresses. If utilized, we would have 900 million authorized shares. You know what that means, everything. More funding - higher amount of dollars in the bank.
So when you read on this board that bankruptcy is imminent or Paulson is not going to fund CYDY anymore, it's bull. In fact, this "talk" we read every day is really rookie investment ideas or just plain fibbing to get people to sell. Let's just take each day at a pace that we cab fully understand it.
In my opinion as a shareholder for the past four years, CYDY will not go bankrupt because Leronlimab is not saline.
All of what you state may be true BUT Tollovid works.
How many other remedies, right now, have no side effects AND are so quick to alleviate symptoms?
New PR this morning: Lalezari part of CYDY now - outside advisor
https://www.cytodyn.com/newsroom/press-releases/detail/600/cytodyn-announces-the-addition-of-leading-experts-in
I don’t know what company you are comparing CytoDyn to - but only one company on this planet has sole use of Leronlimab and it’s not your company that went bankrupt.
So the SP won’t be heading up in May but take a look at Plug by comparison. $17 down from $27 six months ago. We’re all down but Fcel not as much.
Just remember there are shorts holding this stock too, which can drive down the sp